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Abstract
Summary Trabecular bone score (TBS) assesses bone quality
in the lumbar spine using dual-energy X-ray absorptiometry
(DXA) scans. In postmenopausal women with osteoporosis,
denosumab significantly improved TBS independently of
bone mineral density (BMD). This practical technique may
have a role in managing patients with osteoporosis.
Introduction TBS, a gray-level texture index determined from
lumbar spine DXA scans, correlates with bone microarchitecture
and enhances assessment of vertebral fracture risk independently
of BMD. In the FREEDOM study, denosumab increased BMD
and reduced new vertebral fractures in postmenopausal women
with osteoporosis. This retrospective analysis explored the effect
of denosumab on TBS and the association between TBS and
BMD in FREEDOM.
Methods Postmenopausal women with lumbar spine or total
hip BMD T-score <−2.5 and −4.0 or higher at both sites re-
ceived placebo or denosumab 60 mg subcutaneously every
6 months. TBS indices were determined from DXA scans at
baseline and months 12, 24, and 36 in a subset of 285 women
(128 placebo, 157 denosumab) who had TBS values at base-
line and ≥1 postbaseline visit.
Results Baseline characteristics were comparable between
treatment groups; mean (SD) lumbar spine BMD T-score
was −2.79 (0.64), and mean (standard deviation [SD]) TBS
was 1.200 (0.101) overall. In the placebo group, BMD and
TBS increased by ≤0.2% or decreased from baseline at each
visit. In the denosumab group, progressive increases from
baseline at 12, 24, and 36 months were observed for BMD
(5.7, 7.8, and 9.8%) and TBS (1.4, 1.9, and 2.4%). Percentage
changes in TBS were statistically significant compared with
baseline (p < 0.001) and placebo (p ≤ 0.014). TBS was largely
unrelated to BMD, regardless of treatment, either at baseline
or for annual changes from baseline (all r2 ≤ 0.06).
Conclusions In postmenopausal women with osteoporosis,
denosumab significantly improved TBS independently of
BMD.
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Introduction
Measurement of bone mineral density (BMD) using dual-
energy X-ray absorptiometry (DXA) is the standard technique
to assess bone density and fracture risk in postmenopausal
women [1]. Decreased BMD is an established risk factor for
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hip fracture and other osteoporotic fractures [2]. However, use
of BMD lacks sensitivity for predicting vertebral fracture [3].
BMD also does not provide insight into bone microstructure
and altered bone microarchitecture, which are important fac-
tors for fragility fractures [4].
The trabecular bone score (TBS) uses two-dimensional
scans obtained during routine DXA for BMD assessment
and experimental variograms to characterize the three-
dimensional rate of gray-level amplitude variations in trabec-
ular bone [5–8]. Projection of healthy bone microstructure
onto a plane results in a large number of low-amplitude
pixel-to-pixel variations, whereas projection of osteoporotic
bone microstructure onto a plane results in a low number of
high-amplitude pixel-to-pixel variations in a given direction.
Accordingly, an elevated TBS value correlates with better
skeletal microstructure, and a lower TBS value correlates with
more disrupted and weaker skeletal microstructure [8]. The
DXA scans of vertebrae L1–L4 obtained to assess lumbar
spine BMD can also be used to generate TBS, thereby pro-
ducing complementary skeletal information from the same
examination [6]. TBS has been shown to be significantly as-
sociated with direct measurements of bone microarchitecture
and mechanical behavior [5, 8–10] and is predictive of current
[6, 11–16] and future [17–19] fragility fractures in postmeno-
pausal women with primary osteoporosis [19, 20]. TBS can
also be used to assess fracture risk in patients with specific
causes of secondary osteoporosis such as hyperparathyroid-
ism, diabetes, and glucocorticoid treatment [21, 22]. TBS in-
creases the ability of the Fracture Risk Assessment Tool
(FRAX) to categorize fracture risk, and it has been incorpo-
rated into the FRAX model as an adjustment factor [20, 23,
24]. Thus, TBS has been newly included in international
guidelines [25], providing an additional tool to identify and
improve the characterization of patients at risk for fracture and
in need of therapeutic intervention.
Denosumab is a fully human monoclonal antibody against
RANK ligand, which is a key mediator of the formation, ac-
tivation, and survival of osteoclasts [26–29]. In the 3-year
FREEDOM study of 7808 postmenopausal women with os-
teoporosis, subcutaneous administration of denosumab every
6 months was associated with significant reduction in new
vertebral and nonvertebral fractures in women with osteopo-
rosis compared with placebo [30]. A subset of women in the
FREEDOM study participated in a prospective DXA
substudy, in which the results for lumbar spine BMD were
comparable to those from the primary study [31]. The objec-
tive of this retrospective analysis was to explore the effect of
denosumab on TBS and the association between TBS and
lumbar spine BMD in FREEDOM. Although denosumab
therapy does not improve the trabecular connectivity, resorp-
tion spaces and stress risers on trabecular surfaces are filled in,
strengthening existing trabeculae. This in-filling of resorption
cavities results in slight thickening of trabeculae, at least at the
sites of active resorption when denosumab therapy starts, a
change that would be reflected in the TBS.
Materials and methods
Study design
The study design and primary endpoints of the FREEDOM
study [30] and the DXA substudy [31] were reported previ-
ously. FREEDOM was an international, multicenter, random-
ized, double-blind, placebo-controlled study that included
7808 postmenopausal women with osteoporosis. Subjects
were randomized 1:1 centrally, in a double-blinded fashion,
to receive either denosumab 60mg or placebo subcutaneously
every 6 months for 36 months. All subjects received daily
supplementation of calcium (≥1000 mg) and vitamin D
(≥400 IU).
Of the 213 study centers that participated in the
FREEDOM study, 19 centers also participated in the DXA
substudy and performed more frequent BMD assessments
and evaluations of additional skeletal sites for 441 subjects.
These subjects provided separate informed consent to partic-
ipate in the DXA substudy.
Subjects
Postmenopausal women with a BMD T-score lower than
−2.5 at the lumbar spine or total hip and −4.0 or higher at both
sites were eligible for participation in the FREEDOM study if
they were naïve to osteoporosis treatment or had received
prior bisphosphonate treatment for <3 years and not within
12 months of study entry and if they were free of other con-
ditions known to impact bonemetabolism. Aminimum of two
evaluable lumbar vertebrae in the L1–L4 region and one
evaluable hip (left or right) was required for inclusion.
Subjects with at least one severe or more than two moderate
vertebral fractures at screening were excluded.
Study assessments
Lumbar spine BMD assessments in the DXA substudy of the
FREEDOM study were performed at baseline and at 1, 6, 12,
24, and 36 months. BMD was measured by Lunar or Hologic
DXA bone densitometers, and the same machine was used for
all measurements for an individual subject. Lumbar spine
scans included L1–L4 vertebrae; prevalent or incident frac-
tured vertebrae confirmed by X-rays were excluded from the
lumbar spine analysis. DXA scans were submitted to a central
imaging vendor for analysis (Synarc Inc., San Francisco, CA,
USA) who also monitored scanner stability and cross-
calibration throughout the study, as well as the quality and
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reliability of the individual subject scans. The results of the
DXA substudy have been published [31].
This analysis retrospectively applied software (TBS
iNsight® v1.9, Medimaps, Merignac, France) to lumbar spine
DXA scans in a blinded-to-treatment manner to determine the
TBS of subjects who participated in the DXA substudy.
Lumbar spine TBS was calculated as the mean of the individ-
ual measurements for L1–L4 vertebrae, excluding those ver-
tebrae that were not included from BMD assessments because
of evidence of fracture or external artifact. However, vertebrae
excluded from BMD measurement due to osteophytes or de-
generative changes were included in the TBS analyses. Only
DXA scans from recent-generation scanners (GE Healthcare
Prodigy™, iDXA™, Hologic QDR 4500™, Discovery™,
and Horizon™) with sufficient resolution and signal-noise
ratio in the acquired scan can be analyzed by the TBS
iNsight® software. Because of the post hoc retrospective anal-
ysis nature of this study, the DXA scanners were not cross-
calibrated using a dedicated TBS fractal phantom.
Statistical analyses
The analyses included subjects with TBS and lumbar spine
BMD measurements at baseline and at least one postbaseline
visit. Missing data were not imputed. The percentage changes
from baseline in lumbar spine BMD and TBS were analyzed
using a repeated-measures model, adjusting for treatment, vis-
it, baseline value, machine type, treatment-by-visit interaction,
and baseline value-by-machine type interaction. Statistical in-
ferences on differences relative to placebo at each time point
as well as differences relative to baseline were assessed, with
no adjustment for multiplicity. The results were reported as
least-squares means and associated two-sided 95% confidence
intervals for the treatment difference at each time point. Using
the least significant change (LSC) with TBS of 5.82% identi-
fied in a previous study [17], the percentages of subjects with
TBS change ≥LSC were calculated for each time point for
each treatment group. Pearson correlation coefficients were
calculated for the relationships between lumbar spine BMD
and TBS at baseline and for the percentage change from
baseline.
Results
Of the 441 postmenopausal women with osteoporosis
who part icipated in the DXA substudy of the
FREEDOM study, 285 (128 placebo, 157 denosumab)
had measurable TBS data at baseline and at least one
postbaseline visit and were included in this analysis.
Among these subjects, baseline characteristics were
comparable between the placebo and denosumab groups
(Table 1). Mean (SD) age at baseline was 72.5 years
(5.0). Mean (SD) lumbar spine BMD T-score at baseline
was −2.79 (0.64), and mean (SD) TBS at baseline was
1.200 (0.101). Mean values at baseline for BMD and
TBS were lower for Hologic than Lunar bone densitom-
eters in each treatment group. Except for fewer preva-
lent vertebral fractures (6.7 vs 23.6% in the entire
FREEDOM cohort), the baseline characteristics of pa-
tients in the DXA substudy did not differ from those
described in FREEDOM [30].
In the denosumab group, progressive increases from base-
line at 12, 24, and 36 months were observed for lumbar spine
BMD (mean increases of 5.7, 7.8, and 9.8%, respectively) and
TBS (mean increases of 1.4, 1.9, and 2.4%, respectively) (Fig.
1). The changes in both BMD and TBS in the denosumab
group were statistically significant compared with baseline
(all p < 0.001) and placebo (all p ≤ 0.014).
More subjects in the denosumab group than in the placebo
group had TBS gains of 5.82% or greater at 12 months (15 vs
11%; p = 0.271), 24 months (21 vs 9%; p = 0.012), and
36 months (20 vs 6%; p = 0.001).
BMD explained a very small fraction of the variability in
TBS at baseline (r2 = 0.06; Fig. 2). TBS change was also
largely unrelated to BMD change at month 12 (r2 < 0.01 for
placebo and r2 = 0.03 for denosumab), month 24 (r2 < 0.01 for
placebo and r2 = 0.02 for denosumab), and month 36
(r2 = 0.03 for placebo and r2 = 0.05 for denosumab; Fig. 3).





Age (years), mean ± SD 72.3 ± 5.4 72.8 ± 4.7
Body mass index (kg/m2),
mean ± SD
25.1 ± 4.3 25.1 ± 4.1
Race, n (%)
White or Caucasian 108 (84.4) 137 (87.3)
Hispanic or Latino 18 (14.1) 19 (12.1)
Other 2 (1.6) 1 (0.6)
Prevalent vertebral fracture, n (%) 7 (5.5) 12 (7.6)
Lumbar spine BMD, mean ± SD
Either machine, T-score −2.83 ± 0.56 −2.75 ± 0.69
Hologica (g/cm2) 0.74 ± 0.06 0.74 ± 0.07
Lunara (g/cm2) 0.83 ± 0.06 0.86 ± 0.09
TBS, mean ± SD
Either machine 1.200 ± 0.099 1.200 ± 0.103
Hologica 1.193 ± 0.099 1.194 ± 0.103
Lunara 1.229 ± 0.093 1.220 ± 0.102
BMD bone mineral density, SD standard deviation, TBS trabecular bone
score
a Number of subjects: Hologic: 103 placebo, 121 denosumab, and 224
total; Lunar: 25 placebo, 36 denosumab, and 61 total
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Discussion
In this retrospective analysis of a subset of postmenopausal
women with osteoporosis in the FREEDOM study, significant
and progressive increases from baseline at 12, 24, and
36 months were observed for both BMD and TBS in the
denosumab group.
A previous analysis of 92 women from the FREEDOM
study reported that denosumab reduced bone turnover com-
pared with placebo when assessed by bone histomorphometry
of iliac crest bone biopsies and analysis of bone turnover
markers [32]. Reduced bone turnover and increased BMD
following denosumab treatment have been associated with
improvement in trabecular and cortical bone at the spine
[33] and a significant reduction (68%) in new vertebral frac-
tures [30].
TBS derived from existing DXA scans of the lumbar spine
provides information about bone architecture and fracture risk
[13, 17], which could assist physicians in identifying patients
at risk of fracture [22, 25]. TBS has also been shown to reflect
therapeutic responses to osteoporosis treatments [34-36] and
could assist in the monitoring of the effectiveness of a therapy.
Indeed, pharmacologic intervention studies suggest that TBS
improves with treatments that increase BMD, but the magni-
tude of change is less marked than BMD. The change in TBS
also appears to be influenced by the type of therapy for oste-
oporosis. Previous studies have reported greater improvement
in TBSwith an anabolic therapy such as teriparatide compared
with a bisphosphonate [37, 38]. In this study, denosumab was
associated with significantly greater improvement in TBS
than placebo at each of the annual assessments. Our findings
are consistent with results of an open-label study that investi-
gated different treatments, including denosumab [37]. The
results for TBS in this study support its usefulness as an addi-
tional tool in routine clinical practice to assess bone
microarchitecture noninvasively.
The lack of a significant correlation between TBS and
BMD in our study is important for several reasons. Firstly, it
supports the principle that TBS provides a measure of bone
not captured by densitometric techniques; secondly, it pro-
vides complementary information that has proved useful and
practical for patient identification [6, 17]; and lastly, it may
allow for an improved assessment of differences in responses
to diverse therapies for osteoporosis.
A limitation of this analysis was that it included only a
small subset of the total FREEDOM population, precluding
an assessment of the relationship between changes in TBS and
fracture risk reductions. Mean percentage changes from base-
line in lumbar spine BMD at 12, 24, and 36 months in this
analysis were comparable to those reported previously in the
primary analysis of the FREEDOM study [30] and in the
Fig. 1 Percentage change from baseline by visit for lumbar spine BMD
(a) and TBS (b) by treatment group. Based on a repeated-measures model
adjusting for treatment, visit, baseline value, machine type, treatment-by-
visit interaction, and baseline value-by-machine type interaction. Data are
presented as least-squares mean and 95% CI. *p ≤ 0.014 compared with
placebo; †p < 0.001 compared with baseline. BMD bone mineral density,
CI confidence interval, Q6M every 6 months, TBS trabecular bone score
Fig. 2 Relationship between lumbar spine BMD and TBS at baseline.
Pearson correlation: r2 = 0.06. BMD bonemineral density, TBS trabecular
bone score
Osteoporos Int
BMD analysis in the FREEDOM DXA substudy [31].
Because TBS provides distinct information from BMD, it is
possible that the other womenwho participated in FREEDOM
could have TBS responses that differed from those observed
in this subpopulation. Whereas differences in baseline BMD
were observed by machine type in this study, the same ma-
chine was used for all measurements for an individual subject,
and the analyses were adjusted for machine type and other
baseline values. Whereas most subjects had improved BMD
with denosumab treatment, approximately one in three sub-
jects did not have improvement in TBS. Changes in BMD
have been reported to reflect a large portion of the efficacy
of denosumab, with a stronger association for nonvertebral
fractures than vertebral fractures [39]. It is possible that the
combination of BMD and TBS provides a more complete
assessment of fracture risk than either approach alone, but
our small study could not determine whether changes in
TBS accounted for any of the remaining effects of treatment
on fracture risk.
In conclusion, these analyses showed that denosumab treat-
ment in postmenopausal women results in significant and pro-
gressive increases in TBS compared with placebo and base-
line over 3 years. TBS is largely unrelated to BMD, either at
baseline or for changes from baseline during denosumab treat-
ment, supporting the concept that TBS provides distinct infor-
mation, independent of BMD. These results, coupled with the
previous observations that TBS correlates with fracture risk,
suggest that this practical technique may have a role in man-
aging patients with osteoporosis. These results provide impe-
tus for additional investigation of the relationship between
changes in TBS and changes in fracture risk during treatment,
which if established, could support the use of TBS to assist in
selecting the most suitable treatment for an individual patient.
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